Sagimet Biosciences Inc Series A (SGMT) Stock Price, Quote & News

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 561 8600

Website: www.sagimet.com

Address:

155 Bovet Road, Suite 303, San Mateo, United States

SuperErica Oct. 25 at 5:19 PM

$EEIQ one of those hot pennies if this one gets volume will take off quick. $EGG $NTRP $SGMT $XFOR Nice run Friday

0 · Reply

StockOracle22 Oct. 25 at 4:36 PM

$SGMT We need to spread the word. 1,900 followers is weak.

0 · Reply

conclusionsq Oct. 25 at 2:12 PM

$SGMT go $100 plz

0 · Reply

BasiuMisiu Oct. 25 at 9:12 AM

$SGMT This stock still feels way to undervalued given the opportunity of Chinese market. Added some more to my position here.

0 · Reply

StockOracle22 Oct. 25 at 7:42 AM

$SGMT A simple AI search: this is ANNUALLY “The global acne treatment market was valued at approximately USD 11.62 billion in 2024 and is projected to grow to around USD 17.48 billion by 2032.”

0 · Reply

StockScanners Oct. 25 at 1:52 AM

$SGMT keep watch if this holds above 8.60

0 · Reply

BearTamerTrading Oct. 24 at 11:15 PM

🔥What a Day of Plays!🔥 Congrats to all our members who secured profits from today’s premarket live alerts — total domination across the board! 💥 Tickers that moved: $TOVX | $NEUP | $SGMT | $GLUE | $WGRX — all alerted live in premarket before the crowd caught on. That’s what separates us — we find the rockets 🚀 before they take off. 📣 This Monday, all live trading streams are FREE! Come see why our members win daily. Experience every moment — from premarket setups to Squawk Alerts and after-hours plays. 🕕 Schedule (ET): Premarket: 6–9 AM 🎥 https://www.youtube.com/live/WHi6Uebkybk?si=1FNw6MIlf%E2%80%93hzLgk Squawk Alerts: 9:30–3:55 🎙 https://www.youtube.com/live/yz2Alz3yHwA?si=-8_rWV87K_ggHftV After-Hours: 4–6 PM 🌙 https://www.youtube.com/live/qpYexlneJlQ?si=aSDC11ZikZMH2z04 ⚠️Go hit “Notify Me” on each stream now so you’re alerted the moment we go live. Don’t miss your shot to see the next Potential Rocket in real time!💪

0 · Reply

BearTamerTrading Oct. 24 at 10:43 PM

$SGMT Strong Day today bulls. The team and I secured major gains here. I’ll see you guys Monday where we will be hosting all live streams for free, everyone is welcomed to join so you can see the opportunities our members have access to on a daily basis. Set a reminder on the next live trading stream below so you don’t miss out. https://www.youtube.com/live/WHi6Uebkybk?si=c9GsJRoLx5vrQkwh

0 · Reply

isaacwilliams33 Oct. 24 at 10:09 PM

$SGMT https://stocktwits.com/news-articles/markets/equity/sagimet-biosciences-stock-soars-after-positive-data-for-experimental-drug-in-acne-study/cLGJDmDR3tq

0 · Reply

UnicornProfits Oct. 24 at 8:35 PM

What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. only 700k float Are they pumping up ticker CMCT for 300% today!? Looks like all eyes are moving to CMCT now.. Watching: $NTRP $CJET $LAZR $SGMT loking good

1 · Reply

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Oct 14, 2025, 7:00 AM EDT - 11 days ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Oct 14, 2025, 6:00 AM EDT - 11 days ago

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Oct 7, 2025, 9:30 AM EDT - 18 days ago

Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts

Oct 7, 2025, 7:00 AM EDT - 18 days ago

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sep 10, 2025, 7:00 AM EDT - 6 weeks ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 7, 2025, 10:05 PM EDT - 6 weeks ago

Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 29, 2025, 11:19 AM EDT - 2 months ago

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 13, 2025, 7:30 AM EDT - 2 months ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jun 9, 2025, 7:00 AM EDT - 4 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 4, 2025, 1:45 PM EDT - 5 months ago

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Jun 4, 2025, 5:00 AM EDT - 5 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

May 22, 2025, 8:00 AM EDT - 5 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 8, 2025, 6:00 AM EDT - 6 months ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 8 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 7, 2025, 4:27 PM EST - 8 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Nov 14, 2024, 3:56 PM EST - 1 year ago

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 12, 2024, 6:30 AM EST - 1 year ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Oct 18, 2024, 3:10 PM EDT - 1 year ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 11, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 12:05 AM EDT - 1 year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2024, 7:30 AM EDT - 1 year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Jul 31, 2024, 12:24 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 6, 2024, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

May 16, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Jan 25, 2024, 8:58 PM EST - 1 year ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 24, 2024, 1:55 PM EST - 1 year ago

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 23, 2024, 5:45 PM EST - 1 year ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 22, 2024, 11:10 PM EST - 1 year ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 1 year ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Dec 4, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Nov 28, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Nov 22, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 10, 2023, 8:30 AM EST - 2 years ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

SuperErica Oct. 25 at 5:19 PM

$EEIQ one of those hot pennies if this one gets volume will take off quick. $EGG $NTRP $SGMT $XFOR Nice run Friday

0 · Reply

StockOracle22 Oct. 25 at 4:36 PM

$SGMT We need to spread the word. 1,900 followers is weak.

0 · Reply

conclusionsq Oct. 25 at 2:12 PM

$SGMT go $100 plz

0 · Reply

BasiuMisiu Oct. 25 at 9:12 AM

$SGMT This stock still feels way to undervalued given the opportunity of Chinese market. Added some more to my position here.

0 · Reply

StockOracle22 Oct. 25 at 7:42 AM

$SGMT A simple AI search: this is ANNUALLY “The global acne treatment market was valued at approximately USD 11.62 billion in 2024 and is projected to grow to around USD 17.48 billion by 2032.”

0 · Reply

StockScanners Oct. 25 at 1:52 AM

$SGMT keep watch if this holds above 8.60

0 · Reply

BearTamerTrading Oct. 24 at 11:15 PM

0 · Reply

BearTamerTrading Oct. 24 at 10:43 PM

0 · Reply

isaacwilliams33 Oct. 24 at 10:09 PM

$SGMT https://stocktwits.com/news-articles/markets/equity/sagimet-biosciences-stock-soars-after-positive-data-for-experimental-drug-in-acne-study/cLGJDmDR3tq

0 · Reply

UnicornProfits Oct. 24 at 8:35 PM

1 · Reply

Venky_clt Oct. 24 at 8:15 PM

$SGMT 230 ML DOLLAR CO. AT 9 DOLLAR STOCK $IOVA 825 ML DOLLAR CO. AT 2 DOLLAR STOCK LOL.

1 · Reply

FubosX Oct. 24 at 7:40 PM

$SGMT https://finance.yahoo.com/news/denifanstat-achieved-endpoints-treatment-moderate-110000036.html

0 · Reply

StocktwitsNews Oct. 24 at 6:45 PM

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study $SGMT $VXF $DFAU https://stocktwits.com/news/equity/markets/sagimet-biosciences-stock-soars-after-positive-data-for-experimental-drug-in-acne-study/cLGJDmDR3tq

0 · Reply

topstockalerts Oct. 24 at 5:58 PM

$SGMT not a bad place for a swing idea 💡

0 · Reply

BearTamerTrading Oct. 24 at 5:33 PM

$SGMT 🚀 From $3 ➜ $11+ and counting! Back in June, I tried to tell the world this one could take off — but some called it a “scam platform.” Fast-forward, and we banked from a $3 entry to $11+ per share. I even averaged up today for the next leg higher from some shares I left behind 😂 Now with today’s news, let’s see what happens next. Can’t say I didn’t try to help my fellow retail traders spot this one early. 📢 Members: The live Squawk Alerts stream is running until 3:55 PM — then we’re live again for After-Hours trading at 4 PM. Don’t miss it! 🎥 Proof of my original $SGMT alert from June ⬇️ https://www.youtube.com/live/6oUt1S388GQ?si=dxy0hx8zl1BmcRxh

2 · Reply

topstockalerts Oct. 24 at 5:22 PM

$SGMT not bad today.. 🚨

0 · Reply